NASDAQ · XNCR
Xencor, Inc.
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
Loading market information…
NASDAQ · MNPR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Monopar Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Monopar Therapeutics Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.86. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Monopar Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 31, 2025 |
| -$2.23-519.44% vs estimate |
| $0.00 |
| Q3 2024 | Nov 8, 2024 | -$0.37+19.57% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $125.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
$28.71-$0.19 (-0.66%)
Zymeworks Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.39% below the high.
$3.82-$0.06 (-1.55%)
Bicycle Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$1.49-$0.13 (-8.02%)
ADC Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.08% below the high.
$1.22+$0.04 (+3.39%)
ALX Oncology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.14% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$1.50-$0.02 (-1.32%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.65% below the high.
